Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study

Abstract Objectives We conducted a retrospective multi‐centre study to assess the real‐world outcome of regorafenib (REGO) and cabozantinib (CABO) in recurrent/refractory bone tumours (BTs) including osteosarcoma (OST), Ewing sarcoma (EWS) and chondrosarcoma (CS)/extra‐skeletal mesenchymal CS (ESMC)...

詳細記述

書誌詳細

主要な著者:	Hagit Peretz Soroka, Tushar Vora, Jonathan Noujaim, Nicolas Marcoux, Sarah Cohen‐Gogo, Thierry Alcindor, Caroline Holloway, Caroline Rodrigues, Hatim Karachiwala, Saima Alvi, Ursula Lee, Sylvia Cheng, Shantanu Banerji, Sapna Oberoi, Xiaolan Feng, Alannah Smrke, Christine Simmons, Albiruni Abdul Razak, Abha A. Gupta
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2023-09-01
シリーズ:	Cancer Medicine
主題:	cabozantanib CanSaRCC chondrosarcoma Ewing sarcoma osteosarcoma regorafenib
オンライン･アクセス:	https://doi.org/10.1002/cam4.6515
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!